Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care
- 1 April 2003
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 138 (7) , 593-602
- https://doi.org/10.7326/0003-4819-138-7-200304010-00018
Abstract
Hypertension in patients with type 2 diabetes mellitus is a prevalent condition that leads to substantial morbidity and mortality. To evaluate the goals and optimal agents for treatment of hypertension in type 2 diabetes. Review of the medical literature Randomized trials that evaluated the pharmacologic treatment of hypertension in patients with diabetes and reported microvascular and macrovascular outcomes. Studies were identified by using the Cochrane Library, MEDLINE, meta-analyses, review articles, and expert recommendation. The searches of the Cochrane Library and MEDLINE were performed in May 2000 and updated in April 2002. Data were abstracted to standardized forms by a single reviewer and were confirmed by a second reviewer. Treatment of hypertension in type 2 diabetes provides dramatic benefit. Target diastolic blood pressures of less than 80 mm Hg appear optimal; systolic targets have not been as rigorously evaluated, but targets of 135 mm Hg or less are reasonable. Studies that compare drug classes do not suggest obviously superior agents. However, it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensin-converting enzyme (ACE) inhibitors may be the preferred first-line agents for treatment of hypertension in diabetes. -Blockers and calcium-channel blockers are more effective than placebo, but they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; however, study results are inconsistent in this regard. Treatment of hypertension in type 2 diabetes, with blood pressure goals of 135/80 mm Hg, provides dramatic benefits. Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may be the best first-line treatments, although other agents are usually necessary and goals may not be achieved even with three or four agents. Aggressive blood pressure control may be the most important factor in preventing adverse outcomes in patients with type 2 diabetes.Keywords
This publication has 68 references indexed in Scilit:
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994Diabetes Care, 1998
- Effective Postponement of Diabetic Nephropathy With Enalapril in Normotensive Type 2 Diabetic Patients With MicroalbuminuriaDiabetes Care, 1997
- Metabolic Control and Prevalent Cardiovascular Disease in Non-Insulin-dependent Diabetes Mellitus (NIDDM): The NIDDM Patient Outcomes Research TeamThe American Journal of Medicine, 1997
- Predictors of Stroke in Middle-Aged Patients With Non–Insulin-Dependent DiabetesStroke, 1996
- Long-Term Glycemic Control Relates to Mortality in Type II DiabetesDiabetes Care, 1995
- Cardiovascular Morbidity and Mortality in Type 2 Diabetic Patients: a 22‐year Historical Cohort Study in Dutch General PracticeDiabetic Medicine, 1995
- MORTALITY AMONG DIABETICS IN A NATIONAL SAMPLEAmerican Journal of Epidemiology, 1988
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979
- Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up StudyDiabetes, 1974